A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates

Table 2

Cox analysis of fibrate prescriptions in the population, 2005–2010.

Variables	Unadjusted			Adjusted^a
	HR	95% C.I.	𝑃-value	HR	95% C.I.	𝑃-value
Fenofibrate	0.91	0.64–1.31	0.614	1.30	0.82–2.05	0.263
Gemfibrozil	1.10	0.76–1.58	0.614	0.771	0.49–1.22	0.263

^aAdjusted for gender, age, and mean dose.
Multiple Cox regression models were used to estimate the relationship between sex, age, medication, and mean dose of fibrates and development of NODM.